Bq. Zhu et al., EFFECTS OF ETIDRONATE AND LOVASTATIN ON THE REGRESSION OF ATHEROSCLEROSIS IN CHOLESTEROL-FED RABBITS, Cardiology, 85(6), 1994, pp. 370-377
Eighty New Zealand rabbits in eight groups (10 each) were fed a 0.5% c
holesterol diet for 12 weeks. One group served as a control and was sa
crificed at the end of 12 weeks. Seven other groups were shifted to a
normal diet and received a drug(s) or placebo for the second 12 weeks.
The high dose of etidronate (3 mg/kg/day) with lovastatin (6 mg/kg/da
y) significantly reduced the percent of aortic atherosclerotic lesions
[56 +/- 21 vs. 77 +/- 17% (mean +/- SD), p < 0.05] in the regression
study. Compared to the control groups for etidronate and lovastatin, t
he high or low dose (0.15 mg/kg/day) of etidronate significantly reduc
ed aortic standardized plaque volume per unit (18.7 +/- 7.9 or 18.8 +/
- 9.1 vs. 28.4 +/- 11.8 mm.%, p < 0.05). Lovastatin reduced pulmonary
artery maximum plaque thickness (0.13 +/- 0.10 vs. 0.23 +/- 0.11 mm, p
< 0.05). There were no differences in serum lipid and calcium levels
in the control and treated groups. The high dose of etidronate inhibit
ed bone mineralization as expected, whereas the low dose of etidronate
did not. These data suggest that etidronate with lovastatin can regre
ss aortic atherosclerosis in the cholesterol-fed rabbit placed on a no
rmal diet.